With an antisense drug already on the market via its partnership with Novartis
Today brought more good news for shareholders, as the company announced positive results in the phase 2 clinical trials of ISIS 301012. This drug is an experimental cholesterol-lowering drug, another in the company's pipeline of antisense drugs. Antisense drugs, like RNAi technology, aim to halt a disease by targeting and silencing genes at the root of a condition.
This is an important event for shareholders, not only because of the potential blockbuster that this drug could be if and when it makes it to market, but also because it demonstrates the drugmaker's knack for successfully pushing drugs through requisite clinical trials. Despite an impressive run-up in the price of this stock, it still maintains long-term upside potential.
Isis has been wheeling and dealing with some of the large-cap pharmaceuticals who are buying into its technology. On Tuesday, the company received approval from antitrust regulators to proceed with a collaboration agreement with Johnson & Johnson's
For related Foolishness check out: